Table 2.
Baseline characteristics of the included studies
| Study ID | Arms | Sample | Age, y mean (SD) | Gender, Male, n (%) | BMI, kg/m2 mean(SD) | Comorbidities n(%) | Echocardiographic measures | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AF | DM | HTN | Stroke | Functional MR etiology, n (%) | LVEF, % mean(SD) | Transmitral mean gradient, mm Hg mean(SD) | Pulmonary artery systolic pressure, mm Hg mean(SD) | ||||||
| Benito-González et al. 2018 [28] | SAPT, DAPT, VKA, and Dual OAC | 80 | 74.6 (10.1) | 52 (65) | 26.7 (5.1) | 47 (58.8) | 23 (28.8) | 52 (65) | 3 (3.6) | 60 (75) | N/A | N/A | 46.9 (16.2) |
| Hohmann et al. 2022 [27] | DAPT | 157 | 74.6 (10.4 | 103 (65.6) | N/A | 35 (22.3) | 74 (47.1) | 134 (85.4) | N/A | N/A | N/A | N/A | N/A |
| Mono OAC | 261 | 77.8 (7.4) | 152 (58.2) | N/A | 206 (78.9) | 117 (44.8) | 243 (93.1) | N/A | N/A | N/A | N/A | N/A | |
| Duo OAC | 279 | 77.0 (8.2) | 168 (60.2) | N/A | 207 (74.2) | 128 (45.9) | 253 (90.7) | N/A | N/A | N/A | N/A | N/A | |
| Triple OAC | 37 | 77.9 (6.8) | 25 (67.6) | N/A | 23 (62.2) | 16 (43.2) | 33 (89.2) | N/A | N/A | N/A | N/A | N/A | |
| No APT | 282 | 75.9 (9.7) | 179 (63.5) | N/A | 202 (71.6) | 116 (41.1) | 256 (90.8) | N/A | N/A | N/A | N/A | N/A | |
| Körber et al. 2018 [26] | VKA, OAC, SAPT, and DAPT | 347 | 76 (13.7) | 203 (58.5) | 25.3 (4.7) | 194 (55.9%) | 89 (25.6%) | 238 (68.6%) | 44 (12.7%) | 183 (52.7%) | N/A | N/A | N/A |
| Meurin et al. 2008 [25] | VKA | 230 | 59 (14) |
150 (65%) |
N/A | 53 (23) | N/A | N/A | N/A | N/A | 56 (11) | 2.8 (1.7) | N/A |
| No APT | 35 | 60 (15) | 25 (71%) | N/A | 0 (0) | N/A | N/A | N/A | N/A | 57 (10) | 3.2 (2.1) | N/A | |
| Paparella et al. 2016 [33] | SAPT | 286 | 56.3 (17.3) | 180 (62.9) | 25.4 (4.0) | N/A | 16 (5.6) | 145 (50.7) | 5 (1.7) | N/A | N/A | N/A | N/A |
| VKA | 858 | 57.7 (12.9) | 539 (62.8) | 25.0 (4.8) | N/A | 42 (4.9) | 404 (47.1) | 11 (1.3) | N/A | N/A | N/A | N/A | |
| Seeger et al. 2019 [22] | OAC | 136 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SAPT | 118 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Suri et al. 2013 [9] | VKA | 5,963 | 59.67 (13.35) | 3,578 (60.0) | N/A | N/A | 513 (8.6) | 3,305 (55.4) | N/A | N/A | 59.33 (8.9) | N/A | N/A |
| SAPT | 7,119 | 57.33 (12.6) | 4,148 (58.3) | N/A | N/A | 635 (8.9) | 3,933 (55.2) | N/A | N/A | 59 (8.16) | N/A | N/A | |
| Waechter et al. 2022 [19] | No APT | 11 | 72.5 (11) | 8 (72.7) | N/A | 9 (81.8) | 3 (27.3) | 4 (36.4) | 0 (0) | 11 (100) | N/A | N/A | N/A |
| OAC | 146 | 78.9 (7.5) | 86 (58.9) | N/A | 135 (92.5) | 46 (31.5) | 119 (81.5) | 14 (9.6) | 85 (58.2) | N/A | N/A | N/A | |
| OAC + SAPT | 248 | 78.4 (8) | 157 (63.3) | N/A | 234 (94.4) | 78 (31.5) | 216 (87.1) | 31 (12.5) | 144 (58.1) | N/A | N/A | N/A | |
| van der Wall et al. 2018 [31] | VKA | 325 | 60 (13) | 195 (60) | N/A | N/A | 17 (5.4) | 149 (47) | 7 (2.2) | N/A | N/A | N/A | N/A |
| SAPT | 144 | 62 (11) | 85 (59) | N/A | N/A | 5 (3.5) | 74 (51) | 8 (5.6) | N/A | N/A | N/A | N/A | |
| Noohi et al. 2020 [36] | OAC | 153 | 49.9 ± 15 | 60 (39.5%) | N/A | 24 (15.7%) | 7 (4.9%) | 35 (22.9% | N/A | N/A | 44.01 ± 10.4 | N/A | N/A |
| VKA | 144 | 51.9 ± 14.3 | 51 (35.4%) | N/A | 25 (17.4%) | 34 (22.2%) | 58 (40.3%) | N/A | N/A | 46.66 ± 9.2 | N/A | N/A | |
| Valeur et al. 2016 [20] | SAPT | 1437 | Median, 64 | 960 (67%) | N/A | 158 (11%) | 175 (12%) | N/A | 73 (5%) | N/A | N/A | N/A | N/A |
| VKA | 751 | Median, 63 | 559 (74%) | N/A | 86 (10%) | 59 (8%) | N/A | 19 (3%) | N/A | N/A | N/A | N/A | |
| Watt et al. 2020 [32] | VKA | 775 | 57 ± 13 | 442(57.0%) | N/A | N/A | 74(9.6%) | 347(44.8%) | N/A | N/A | 57 ± 12% | N/A | N/A |
| SAPT | 322 | 55 ± 15 | 168(52.2%) | N/A | N/A | 38(11.8%) | 153(47.5%) | N/A | N/A | 57 ± 15% | N/A | N/A | |
| BMI, Body mass index, AF, Atrial Fibrillation, HTN, Hypertension, DM, Diabetes mellitus, MR, mitral regurgitation, LVEF, Left ventricular ejection fraction, DAPT, Dual antiplatelet therapy, SAPT, Single antiplatelet therapy, OAC, oral anticoagulant, VKA, Vitamin K antagonist, APT, antiplatelet therapy | |||||||||||||